Skip to main content

Advertisement

SpringerLink
Log in

An examination of the prevalence of IDF- and ATPIII-defined metabolic syndrome in an Irish screening population

  • Original Article
  • Published:
Irish Journal of Medical Science Aims and scope Submit manuscript

Abstract

Objectives

To investigate the prevalence of ATPIII- and IDF-defined metabolic syndrome (MetS) in an Irish screening population and to determine the calculated cardiovascular risk for each group.

Design

A total of 1,716 subjects were enrolled over a 12-month period.

Main outcomes

The ATPIII-defined prevalence of MetS in this population was 13.2%. Using IDF criteria, 21.4% of subjects were identified as having the MetS. Correlation between the two definitions was high; however, IDF criteria identified an additional 9.5% (n = 164) of the population as having MetS, which ATPIII criteria failed to recognise.

Conclusion

We noted a higher prevalence of MetS in the studied population when defined by IDF criteria. However, those identified by IDF and not by ATPIII definition did not have a higher cardiovascular risk score by either Framingham or European Score than those without MetS. Thus, application of the ATPIII definition of MetS, may be the more practical.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689. doi:10.2337/diacare.24.4.683

    Article  PubMed  CAS  Google Scholar 

  2. Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 288:2709–2716. doi:10.1001/jama.288.21.2709

    Article  PubMed  Google Scholar 

  3. Trevisan M, Liu J, Bahsas FB, Menotti A (1998) Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 148:958–966

    PubMed  CAS  Google Scholar 

  4. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM (2004) Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 27:2676–2681. doi:10.2337/diacare.27.11.2676

    Article  PubMed  Google Scholar 

  5. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

  6. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497. doi:10.1001/jama.285.19.2486

    Article  Google Scholar 

  7. National Institutes of Health Executive summary (2001) In: Third Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Washington, DC, US Govt. Printing Office (NIH publ. no. 01–3670)

  8. Ford ES (2004) Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am 33:333–350. doi:10.1016/j.ecl.2004.03.004

    Article  PubMed  Google Scholar 

  9. The IDF consensus worldwide definition of the metabolic syndrome (2005) Available from http://www.idf.org/webdata/docs/ (article online)

  10. Tenenbaum A, Motro M, Schwammenthal E, Fisman E (2004) Macrovascular complications of metabolic syndrome: an early intervention is imperative. Int J Cardiol 97:167–172. doi:10.1016/j.ijcard.2003.07.033

    Article  PubMed  Google Scholar 

  11. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847

    PubMed  CAS  Google Scholar 

  12. Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003. doi:10.1016/S0195-668X(03)00114-3

    Article  PubMed  CAS  Google Scholar 

  13. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP (2005) The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 21:1157–1159. doi:10.1185/030079905X53333

    Article  PubMed  Google Scholar 

  14. Guerrero-Romero F, Rodriguez-Moran M (2005) Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions. Diabetes Care 28:2588–2589. doi:10.2337/diacare.28.10.2588a Letter

    Article  PubMed  Google Scholar 

  15. Ford ES (2005) Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care 28:2745–2749. doi:10.2337/diacare.28.11.2745

    Article  PubMed  Google Scholar 

  16. Lorenzo C, Serrano-Rios M, Mt Martinez-Larrad et al (2006) Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care 29:685–691. doi:10.2337/diacare.29.03.06.dc05-1796

    Article  PubMed  Google Scholar 

  17. Sauerwein HP (2006) The dysmetabolic syndrome: epidemiology and etiology. Nestle Nutr Workshop Ser Clin Perform Programme 11:1–13. doi:10.1159/000094397

    Article  PubMed  CAS  Google Scholar 

  18. Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A, GREECE-METS Collaborative Group (2007) Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 117(2):204–210

    Article  PubMed  Google Scholar 

  19. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P et al (2006) Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 29:901–907. doi:10.2337/diacare.29.04.06.dc05-2011

    Article  PubMed  Google Scholar 

  20. Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive Summary. Circulation 112:e285–e290. doi:10.1161/CIRCULATIONAHA.105.169405

    Article  Google Scholar 

  21. Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062. doi:10.1016/S0140-6736(05)67402-8

    Article  PubMed  Google Scholar 

  22. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23:469–480. doi:10.1111/j.1464-5491.2006.01858.x

    Article  PubMed  CAS  Google Scholar 

  23. Assmann G, Guerra R, Fox G, Cullen P, Schulte H, Willett D, Grundy SM (2007) Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States. American and European populations 99(4):541–548

    Google Scholar 

  24. Joint British recommendations on prevention of coronary heart disease in clinical practice (1998) British Cardiac Society, British Hyperlipidemia Association, British Hypertension Society, British Diabetic Association. Heart 80(suppl 2):S1–S29

  25. Preventing coronary heart disease in high risk patients (2000) In: National service framework for coronary heart disease. Department of Health, London, pp 1–32

  26. Zarich S, Luciano C, Hulford J, Abdullah A (2006) Prevalence of metabolic syndrome in young patients with acute MI: does the Framingham Risk Score underestimate cardiovascular risk in this population? Diab Vasc Dis Res 3:103–107

    Article  PubMed  Google Scholar 

  27. DECODE Study Group (2007) Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study. Eur J Cardiovasc Prev Rehabil 14:192–199

    Article  Google Scholar 

  28. Lawlor DA, Smith GD, Ebrahim S (2006) Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women’s Heart and Health Study. Diabetologia 49:41–48

    Article  PubMed  CAS  Google Scholar 

  29. Wilson PAW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

The authors have no financial conflicts to declare.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland

    D. F. Waterhouse, A. M. McLaughlin & D. O’Shea

  2. Department of Preventative Medicine, Blackrock Clinic, Co Dublin, Ireland

    F. Sheehan

Authors
  1. D. F. Waterhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. M. McLaughlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Sheehan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. O’Shea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. M. McLaughlin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waterhouse, D.F., McLaughlin, A.M., Sheehan, F. et al. An examination of the prevalence of IDF- and ATPIII-defined metabolic syndrome in an Irish screening population. Ir J Med Sci 178, 161–166 (2009). https://doi.org/10.1007/s11845-008-0269-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-008-0269-1

Keywords

Search

Navigation